What is the latest AKUMS stock price?
The latest stored price for AKUMS is Rs 761.15 as of 2026-11-03.
gimli
AKUMS stock AI analysis
AKUMS Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
AKUMS DRUGS AND PHARMA L is a small-cap stock in Healthcare. This Gimli page shows the latest available AKUMS price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹761.15
1W return
+5.83%
1M return
-6.39%
3M return
+11.74%
6M return
+39.07%
1Y return
+62.76%
Market cap
₹11,653.37 cr
PE
49.26
PB
3.50
ROE
+7.40%
ROCE
+15.60%
RSI
54.44
Turnover
₹141.48 cr
Why it can matter in screens
- Momentum: AKUMS is below 50DMA, above 200DMA; RSI is 54.44.
- Returns: 1D +3.82%, 1W +5.83%, 1M -6.39%, 3M +11.74%, 1Y +62.76%.
- Trend levels: 52W high ₹838.80, 52W low ₹517.00, off high -9.26%.
- Liquidity: latest turnover is ₹141.48 cr; volume vs 20D is +6.49%.
- Valuation/profitability: PE 49.26, PB 3.50, ROE +7.40%, ROCE +15.60%.
- Growth: 3Y sales CAGR +7.85%, 3Y profit CAGR +39.07%.
Quick Answers
Is AKUMS above its 50DMA and 200DMA?
AKUMS is below 50DMA, above 200DMA. The latest 50DMA is 764.45 and the latest 200DMA is 605.83.
What are AKUMS PE, ROE and ROCE?
AKUMS has PE 49.26, ROE +7.40%, and ROCE +15.60% in Gimli's latest available snapshot.
How has AKUMS performed recently?
AKUMS has returned -6.39% over 1 month, +11.74% over 3 months, and +62.76% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 418.38 cr | 74.61 cr | 44.84 cr | 6.53 |
| 2026-03-31 | 1,157.87 cr | 185.23 cr | 84.61 cr | 5.53 |
| 2025-12-31 | 1,159.59 cr | 162.96 cr | 66.32 cr | 4.33 |
| 2025-09-30 | 1,017.53 cr | 123.44 cr | 40.78 cr | 2.66 |
| 2025-06-30 | 1,024.03 cr | 150.83 cr | 63.48 cr | 4.15 |
| 2025-03-31 | 1,055.55 cr | 119.67 cr | 147.62 cr | 9.64 |
| 2024-12-31 | 1,010.41 cr | 140.71 cr | n/a | nan |
| 2024-09-30 | 1,033.09 cr | 138.35 cr | n/a | nan |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 4,359.02 cr | 630.73 cr | 255.19 cr | 16.67 |
| 2025-03-31 | 4,118.16 cr | 533.30 cr | 338.18 cr | 22.60 |
| 2024-03-31 | 4,019.68 cr | 130.61 cr | -4.04 cr | -0.28 |
| 2023-03-31 | 3,474.76 cr | 309.08 cr | 94.86 cr | 6.03 |
| 2022-03-31 | 1,220.54 cr | -82.18 cr | -381.78 cr | -16.04 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 5,446.97 cr | 386.00 cr | 157.43 cr | 3,331.12 cr |
| 2025-03-31 | 4,113.44 cr | 101.19 cr | 88.21 cr | 3,063.61 cr |
| 2024-03-31 | 3,516.36 cr | 111.05 cr | 565.23 cr | 720.49 cr |
| 2023-03-31 | 3,266.53 cr | 51.61 cr | 619.09 cr | 723.37 cr |
| 2022-03-31 | 3,069.05 cr | 55.14 cr | 394.98 cr | 625.17 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 1,181.20 cr | 950.67 cr | n/a |
| 2025-03-31 | 465.20 cr | 192.88 cr | n/a |
| 2024-03-31 | 498.26 cr | 186.85 cr | n/a |
| 2023-03-31 | 176.63 cr | -152.16 cr | n/a |
| 2022-03-31 | 31.85 cr | -225.73 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +75.26% | +1.91% | +13.44% | +9.77% | +6.66% | +0.00% |
| 2026-03-31 | +75.26% | +1.37% | +14.35% | +10.95% | +6.29% | +0.00% |
| 2025-12-31 | +75.26% | +1.15% | +14.40% | +11.23% | +6.46% | +0.00% |
| 2025-09-30 | +75.26% | +2.28% | +9.28% | +6.44% | +10.46% | +0.00% |
| 2025-06-30 | +75.26% | +4.24% | +8.85% | +6.73% | +8.93% | +0.00% |
| 2025-03-31 | +75.26% | +5.77% | +7.40% | +6.11% | +8.85% | +0.00% |
| 2024-12-31 | +75.26% | +6.36% | +7.00% | +5.54% | +8.65% | +0.00% |
| 2024-09-30 | +75.26% | +7.34% | +7.52% | +5.18% | +7.15% | +0.00% |
| 2024-08-02 | +75.26% | +5.32% | +7.60% | +3.07% | +9.09% | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 424,658.30 cr | 35.053345 | +15.50% | +3.72% |
| DIVISLAB | DIVI S LABORATORIES LTD | 267,167.60 cr | 91.684145 | +18.37% | +47.91% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 157,377.11 cr | 74.094685 | +16.87% | +28.16% |
| LAURUSLABS | LAURUS LABS LIMITED | 125,408.69 cr | 114.827348 | +21.77% | +138.16% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 124,833.39 cr | 27.818646 | +16.04% | +26.46% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 121,354.29 cr | 57.614911 | +22.62% | +7.87% |
| DRREDDY | DR. REDDY S LABORATORIES | 113,923.95 cr | 40.698752 | +7.80% | +14.41% |
| CIPLA | CIPLA LTD | 112,841.65 cr | 38.950805 | +8.80% | -7.58% |
Try these prompts
- Analyze AKUMS DRUGS AND PHARMA L with valuation, momentum and industry peers
- Compare AKUMS with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare AKUMS with other Healthcare stocks
Data snapshot: 2026-11-03. Not investment advice.